Physician profile
Michael Holsten
NPI 1700294899
$2,004.50
in general payments reported to CMS, 2019-2025
17 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $529 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.54 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $255.35 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $247.67 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $172.04 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $153.90 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.43 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $86.19 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $85.42 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $81.29 | 2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $79.98 | 2024-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $76.69 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Collegium Pharmaceutical, INC. | $67.36 | 2025 | Jornay Pm |
| Indivior INC. | $65.82 | 2025 | Sublocade |
| Bausch Health US, LLC | $51.47 | 2025 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $47.89 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $37.64 | 2024 | Xelstrym |
| Tris Pharma INC | $19.82 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Holsten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.